Developing STK-001: An Oligonucleotide Treatment for Dravet Syndrome, Treatment Beyond Seizure Control
Time: 11:40 am
day: Day Two
Details:
- Exploring the clinical trial design and global expansion for STK-001
- Assessing the enrolment, dosing strategies and secondary endpoints chosen
- Evaluating safety and pharmacokinetic data from the SAD portion of the MONARCH study
